Asiaticoside tablets tested for weight loss in adults with obesity
Tests asiaticoside tablets, an herbal-derived drug, in adults with overweight or obesity.
Plain-language title generated from the registry record
Registry title: Asiaticoside for Treating Overweight/Obesity
Key facts
- Where
- Shanghai, ChinaSee the site
Where in China
- Zhongshan Hospital,Fudan UniversityShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shanghai Zhongshan Hospital
- Trial code
- NCT07241533
- Record updated
- 24 December 2025
- Original description
Centella asiatica is a traditional herbal medicine widely used in China and Southeast Asia for treating various conditions. Preclinical studies have shown that madecassic acid glycosides, including asiaticoside and madecassoside, can significantly reduce body weight gain, adipose tissue mass, and serum triglyceride levels in high-fat diet-induced obese mice. These compounds also improve hepatic steatosis and insulin resistance. This exploratory, interventional study aims to evaluate the clinical efficacy of orally administered asiaticoside tablets in adults with overweight or obesity.Read full original descriptionShow less
A Clinical Efficacy Study of Asiaticoside for Treating Overweight/Obesity
Centella asiatica is a traditional herbal medicine widely used in China and Southeast Asia for treating various conditions. Preclinical studies have shown that madecassic acid glycosides, including asiaticoside and madecassoside, can significantly reduce body weight gain, adipose tissue mass, and serum triglyceride levels in high-fat diet-induced obese mice. These compounds also improve hepatic steatosis and insulin resistance. This exploratory, interventional study aims to evaluate the clinical efficacy of orally administered asiaticoside tablets in adults with overweight or obesity.
Inclusion: Adults aged 18 years or older, male or female; Overweight or obesity, defined as a body mass index (BMI) of 24.0-45.0 kg/m²; Able and willing to provide written informed consent.
Exclusion: Currently receiving other anti-obesity treatments, a previous history of bariatric surgery, or a >5% reduction in body weight within the past 3 months; type 1 or type 2 diabetes mellitus or currently taking hypoglycemic medications; Active pulmonary tuberculosis, malignant tumors, human immunodeficiency virus (HIV) infection, or other severe infectious or immunocompromising conditions; Severe cardiovascular diseases, including angina pectoris, myocardial infarction, or stroke within the past 6 months; Severe gastrointestinal disorders, or a history of gastrointestinal surgery within the past year; Secondary causes of obesity, including Cushing's syndrome, primary hypothyroidism, hypothalamic obesity, acromegaly; or drug-induced obesity (e.g., antipsychotics, glucocorticoids); Unable to complete a 3-month follow-up due to health conditions or relocation; Other conditions considered by investigators as unsuitable for participation; Severe liver injury (AST or ALT > 3 times the upper limit of normal) or severe renal dysfunction/end-stage renal disease (eGFR < 30 mL/min/1.73 m²); Current smoker or habitual smoker within the past 3 months; Pregnancy or planning pregnancy, or breastfeeding; Participation in any clinical study within the past 4 weeks.